Thanks to a computational drug repositioning approach using K-RAS-driven signatures, authors repurposed 5-aza-2’-deoxycytidine (decitabine), an FDA-approved drug, to inhibit K-RAS-dependent PDAC tumor growth. This evidence concerns the gene KRAS and neoplasm.